“HPR, a preclinical CRO based in Japan, specializing in pharmacological evaluation of novel therapeutics in nonhuman primate disease models, announces operation of its own 1.5T GE Healthcare MRI beginning this month, March 2021.
The MRI would be completely managed and operated by HPR, thereby increasing access to in vivo imaging for HPR nonhuman primate studies.
“CEO Dr. Hiroyuki Takamatsu notes, “In vivo imaging has become a significant outcome measure in a number of our contract studies. To address future needs, we have made a commitment to our infrastructure by doubling MRI capacity, in terms of both staffing and equipment.
We are grateful to our previous and current clients.“
For more information about HPR, please visit our website, www.hpharmausa.com